Exacerbation of pemphigus by rifampicin

Miyagawa, Shuji; Yamashina, Yukio; Okuchi, Toshie; Konoike, Yoshizumi; Kaburagi, Takashi; Sakamoto, Kenichi

doi:10.1111/j.1365-2133.1986.tb04882.x

Cited by 19 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA-A polymorphisms have been associated with PV in Jewish as well as in Chinese patients (13,17). Variations within HLA-A, HLA-B and HLA-C have additionally been noted amongst patients with PV, although these variations were similarly population dependent (23)(24)(25). Polymorphisms of the transporter-associated antigenprocessing genes (TAP1 and TAP2), transporters required for the loading of certain antigens to HLA class-1 molecules, were not found to be significant in patients with PV (26).…”

Section: Prevalence Of Human Leucocyte Antigens In Pvmentioning

confidence: 99%

Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris

Amber

Staropoli

Shiman

et al. 2013

Experimental Dermatology

View full text Add to dashboard Cite

Pemphigus vulgaris is a life-threatening autoimmune blistering disease caused by anti-desmoglein IgG autoantibodies that finally lead to acantholysis presenting clinically as progressive blistering. Whilst the production of pathogenic antibodies is key to the development of pemphigus vulgaris, many immunological steps are required prior to autoantibody induction. We review advances in the understanding of these immunologic processes with a focus on human leucocyte antigen polymorphisms and antigen recognition, epitope spreading, central and peripheral tolerance, T helper differentiation, induction of pro-and antiinflammatory cytokines and T-cell regulation of B cells. Targeting autoaggressive T cells as regulators and stimulators of B-cell antibody production should allow for more specific therapeutic immune interventions, avoiding the global immunosuppression seen with many commonly used immunosuppressants in pemphigus vulgaris.

show abstract

Section: Prevalence Of Human Leucocyte Antigens In Pvmentioning

confidence: 99%

Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris

Amber

Staropoli

Shiman

et al. 2013

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…However, there have been isolated reports of erythema multiforme, toxic epidermal necrolysis, 1 pemphigus 2 and thrombocytopaenic purpura 3 . Rifampicin has also been reported to exacerbate pre‐existing pemphigus 4 and porphyria cutanea tarda 5 …”

Section: Reportmentioning

confidence: 99%

Rifampicin-induced lupus erythematosus

Patel

Anstey

2001

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Rifampicin has been prescribed throughout the world for over 20 years, yet only four cases of rifampicin-induced lupus erythematosus (LE) have been reported. Rifampicin-induced LE is associated with combination therapy with clarithromycin or ciprofloxacin. These drugs are all metabolized through the cytochrome P450 liver enzyme system and combined usage may lead to higher rifampicin blood levels. Drug-induced LE differs from systemic LE; cutaneous manifestations, although uncommon, are an important clue to the diagnosis. We report a case of rifampicin-induced LE presenting with florid cutaneous features.

show abstract

“…1D). Four cases have been attributed to rifampin, 35 − 38 two being exacerbations of pre‐existing pemphigus vulgaris in patients on steroid maintenance. Two patients developed a first onset of pemphigus about 9 months after the drug was started.…”

Section: Phenol Drugsmentioning

confidence: 99%